ObjectiveTo investigate the clinical effect of beraprost combined with rosuvastatin in the prevention of acute renal injury induced by contrast medium. Methods200 patients with coronary heart disease, who received coronary angiography, were randomly divided into control group, beraprost group, rosuvastatin group, combined treatment group, with 50 cases in each group. 200 patients were treated with anti platelet, anti angina, control blood pressure, blood glucose, etc, on the basis of conventional treatment, control group were received placebo; beraprost group received beraprost, 40ug per time,3 times a day; rosuvastatin group received oral rosuvastatin 10mg with once a night, combined treatment group would be the combination of the 2 methods. Serum creatinine, Cystatin C, beta 2 microglobulin, high sensitivity C reactive protein of the four groups were observed, and incidence of contrast induced nephropathy were calculated. ResultsAfter treatment, the morbidity of contrast induced nephropathy in combined treatment group was 8%, which was significantly lower than that in the other three groups; the differences of serum creatinine, Cystatin C, beta 2 microglobulin, high sensitivity C reactive protein in the four groups had no significant difference (P＞0.05) before coronary angiography, but 24 and 72 hours after exposure to contrast medium, the concentration of Cystatin C, beta 2 microglobulin, high sensitivity C reactive protein in combined treatment group was significantly lower than that in the control group (P＜0.05) , and 72 hours after exposure to contrast medium, the level of serum creatinine in combined treatment group was significantly lower than that in the control group (P＜0.05) ConclusionsThe beraprost combined with rosuvastatin has obvious effect in the prevention of acute renal injury induced by contrast medium and high safety, which worthy of clinical promotion.

• ref